• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Grifols S.A. (Amendment)

    2/9/24 2:45:34 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRFS alert in real time by email
    SC 13G/A 1 Grifols_SA.txt 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) * Grifols SA (Name of Issuer) Class B shares (Title of Class of Securities) E5706X223 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1 (b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the ACT but shall be subject to all other provisions of the Act (however, see the Notes). SEC 1745 (3-98) CUSIP No.E5706X223 1. Names of Reporting Persons. Brandes Investment Partners, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0704072 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 7. Sole Dispositive Power 8. Shared Dispositive Power 13,480,174 ORDs and 14,059,501 ADRs 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,480,174 ORDs and 14,059,501 ADRs 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 10.53 % 12. Type of Reporting Person (See Instructions) IA, PN CUSIP No.E5706X223 1. Names of Reporting Persons. CO-GP, LLC I.R.S. Identification Nos. of above persons (entities only). 73-1677697 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 7. Sole Dispositive Power 8. Shared Dispositive Power 13,480,174 ORDs and 14,059,501 ADRs 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,480,174 ORD shares and 14,059,501 ADR shares are deemed to be beneficially owned by CO- GP, LLC as a control person of the investment adviser. CO-GP, LLC disclaims any direct ownership of the shares reported in this Schedule 13G, except for an amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 10.53 % 12. Type of Reporting Person (See Instructions) CO, OO (Control Person) CUSIP No.E5706X223 1. Names of Reporting Persons. Brandes Worldwide Holdings, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0836630 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 7. Sole Dispositive Power 8. Shared Dispositive Power 13,480,174 ORDs and 14,059,501 ADRs 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,480,174 ORD shares and 14,059,501 ADR shares are deemed to be beneficially owned by Brandes Worldwide Holdings, L.P., as a control person of the investment adviser. Brandes Worldwide Holdings, L.P. disclaims any direct ownership of the shares reported in this Schedule 13G. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 10.53 % 12. Type of Reporting Person (See Instructions) PN, OO (Control Person) CUSIP No.E5706X223 1. Names of Reporting Persons. Glenn Carlson I.R.S. Identification Nos. of above persons (entities only). 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization USA Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 7. Sole Dispositive Power 8. Shared Dispositive Power 13,480,174 ORDs and 14,059,501 ADRs 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,480,174 ORD shares and 14,059,501 ADR shares are deemed to be beneficially owned by Glenn Carlson, a control person of the investment adviser. Mr. Carlson disclaims any direct ownership of the shares reported in Schedule 13G, except for the amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 10.53 % 12. Type of Reporting Person (See Instructions) IN, OO (Control Person) Item 1(a) Name of Issuer: Park Aerospace Corp. Item 1(b) Address of Issuers Principal Executive Offices: 486 N. Oliver Rd., Bldg. Z, Newton City/County Airport, Newton, KS 67114 Item 2(a) Name of Person Filing: (i) Brandes Investment Partners, L.P. (ii) CO-GP, LLC. (iii) Brandes Worldwide Holdings, L.P. (iv) Glenn Carlson Item 2(b) Address of Principal Business office or, if None, Residence: (i) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (ii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iv) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 Item 2(c) Citizenship (i) Delaware (ii) Delaware (iii) Delaware (iv) USA Item 2(d) Title of Class Securities: Common Shares Item 2(e) CUSIP Number: E5706X223 Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(ii)(F). (g) [ ] A parent holding company or control person in accordance with 240.13d- 1(b)(1)(ii)(G). (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). (j) [x] Group, in accordance with 240.13d- 1(b)(1)(ii)(J). This statement is filed by Brandes Investment Partners, L.P., an investment adviser registered under the Investment Advisers Act of 1940, its control persons and its holding company. (See, also, Exhibit A.) Item 4. Ownership: (a) Amount Beneficially Owned: 13,480,174 ORDs and 14,059,501 ADRs (b) Percent of Class: 10.53 % (c) Number of shares as to which the joint filers have: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 13,480,174 ORDs and 14,059,501 ADRs Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ?. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. See Exhibit A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification: (a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 9, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner CO-GP, LLC its General Partner CO-GP, LLC By: /s/ Glenn Carlson Glenn Carlson, General Partner BRANDES WORLDWIDE HOLDINGS, L.P. By: /s/ Glenn Carlson Glenn Carlson of CO- GP, LLC its General Partner By: /s/ Glenn Carlson Glenn Carlson, Control Person EXHIBIT A Identification and Classification of Members of the Group Pursuant to Rule 13d-1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, the members of the group making this joint filing are identified and classified as follows: Name: Brandes Investment Partners, L.P. (the Investment Adviser) Classification: Investment adviser registered under Investment Advisers Act of 1940 Co-GP, LLC A control person of the Investment Adviser Brandes Worldwide Holdings, L.P. A control person of the Investment Adviser Glenn Carlson A control person of the Investment Adviser EXHIBIT B Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d- 1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the Act) by and among the parties listed below, each referred to herein as a Joint Filer. The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1. Dated: February 9, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner of Co-GP, LLC. Co-GP, LLC. By: /s/ Glenn Carlson Glenn Carlson, General Partner EXHIBIT C Disclaimer of Beneficial Ownership Co-GP, LLC, Brandes Worldwide Holdings, L.P., Glenn Carlson, and Jeff Busby disclaim beneficial interest as to the shares referenced above, except for an amount equal to substantially less than one percent of the shares reported on this Schedule 13D. None of these entities or individuals holds the above- referenced shares for its/his own account except on a de minimis basis. /s/Glenn Carlson Glenn Carlson /s/Jeff Busby Jeff Busby
    Get the next $GRFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRFS

    DatePrice TargetRatingAnalyst
    2/12/2025Overweight
    Morgan Stanley
    3/12/2024Hold → Sell
    Deutsche Bank
    4/12/2023Equal-Weight → Overweight
    Morgan Stanley
    3/3/2023Overweight → Equal-Weight
    Morgan Stanley
    2/16/2023Underweight → Equal Weight
    Barclays
    1/18/2023Hold → Buy
    Jefferies
    4/8/2022Equal-Weight
    Morgan Stanley
    11/5/2021Buy → Hold
    Deutsche Bank
    More analyst ratings

    $GRFS
    Financials

    Live finance-specific insights

    See more
    • Grifols acquires its first plasma donation center in Canada

      BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers

      1/4/22 12:30:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

      Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0

      5/30/25 4:05:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

      ‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global

      1/14/25 6:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

      Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac

      1/13/25 10:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Grifols S.A.

      SC 13G/A - Grifols SA (0001438569) (Subject)

      11/14/24 11:46:03 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Grifols S.A. (Amendment)

      SC 13G/A - Grifols SA (0001438569) (Subject)

      2/9/24 2:45:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Grifols S.A.

      SC 13G - Grifols SA (0001438569) (Subject)

      2/9/24 2:21:17 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    SEC Filings

    See more
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      6/5/25 3:58:16 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/12/25 12:36:55 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/6/25 12:01:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

      BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

      4/18/23 10:30:00 AM ET
      $GRF
      $GRFS
      Finance/Investors Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

      Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)

      10/3/22 12:52:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Grifols, S.A.

      Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight

      2/12/25 9:09:54 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. downgraded by Deutsche Bank

      Deutsche Bank downgraded Grifols, S.A. from Hold to Sell

      3/12/24 1:36:28 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. upgraded by Morgan Stanley

      Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight

      4/12/23 8:07:28 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care